Evidence map›Paper›PMID 27256982›Full record

ArticleOncotarget2016

Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas.

Magdalena Skubal, Gerrit H Gielen, Anke Waha, Marco Gessi, Lech Kaczmarczyk, Gerald Seifert, Dorothee Freihoff, Johannes Freihoff, Torsten Pietsch, Matthias Simon and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Magdalena SkubalInstitute of Cellular Neurosciences, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Gerrit H GielenInstitute of Neuropathology, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Anke WahaInstitute of Neuropathology, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Marco GessiInstitute of Neuropathology, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Lech KaczmarczykInstitute of Cellular Neurosciences, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Gerald SeifertInstitute of Cellular Neurosciences, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Dorothee FreihoffInstitute of Neuropathology, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Johannes FreihoffInstitute of Neuropathology, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Torsten PietschInstitute of Neuropathology, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Matthias SimonInstitute of Neurosurgery, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Martin TheisInstitute of Cellular Neurosciences, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Christian SteinhäuserInstitute of Cellular Neurosciences, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
Andreas WahaInstitute of Neuropathology, Medical Faculty, University of Bonn, 53105 Bonn, Germany.
University of Bonn · DEGerman Center for Neurodegenerative Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytoplasmic polyadenylation element binding proteins (CPEBs) are auxiliary translational factors that associate with consensus sequences present in 3'UTRs of mRNAs, thereby activating or repressing their translation. Knowing that CPEBs are players in cell cycle regulation and cellular senescence prompted us to investigate their contribution to the molecular pathology of gliomas-most frequent of intracranial tumors found in humans. To this end, we performed methylation analyses in the promoter regions of CPEB1-4 and identified the CPEB1 gene to be hypermethylated in tumor samples. Decreased expression of CPEB1 protein in gliomas correlated with the rising grade of tumor malignancy. Abundant expression of CPEBs2-4 was observed in several glioma specimens. Interestingly, expression of CPEB3 positively correlated with tumor progression and malignancy but negatively correlated with protein phosphorylation in the alternatively spliced region. Our data suggest that loss of CPEB3 activity in high-grade gliomas is caused by expression of alternatively spliced variants lacking the B-region that overlaps with the kinase recognition site. We conclude that deregulation of CPEB proteins may be a frequent phenomenon in gliomas and occurs on the level of transcription involving epigenetic mechanism as well as on the level of mRNA splicing, which generates isoforms with compromised biological properties.

Indexed as

Alternative SplicingBrain NeoplasmsCell Line, TumorDisease ProgressionDNA MethylationFemaleGene Expression Regulation, NeoplasticGliomaHumansMaleNeoplasm GradingPhosphorylationProtein IsoformsRNA-Binding ProteinsRNA IsoformsRNA, MessengerCPEB3 protein, humanProtein IsoformsRNA-Binding ProteinsRNA IsoformsRNA, MessengerCPEBDNA methylationexpressiongliomasplicing

Identifiers

PMID27256982
PMCPMC5173104
OpenAlexW2415966994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.